Cullinan Therapeutics Inc (CGEM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2020 | 12-2019 | 12-2017 | 12-2006 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -59,458 | -21,654 | N/A | N/A |
| Depreciation Amortization | 62 | 70 | N/A | N/A |
| Accounts payable and accrued liabilities | 5,581 | 639 | N/A | N/A |
| Other Working Capital | 6,851 | 135 | N/A | N/A |
| Other Operating Activity | 17,192 | -87 | 0 | 0 |
| Operating Cash Flow | $-29,772 | $-20,897 | $N/A | $N/A |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -10 | -20 | N/A | N/A |
| Net Acquisitions | 1,450 | N/A | N/A | N/A |
| Purchase Of Investment | -69,763 | -35,380 | N/A | N/A |
| Sale Of Investment | 62,903 | N/A | N/A | N/A |
| Investing Cash Flow | $-5,420 | $-35,400 | $N/A | $N/A |
| Cash Flows From Financing Activities | ||||
| Common Stock Issued | 145,506 | N/A | N/A | N/A |
| Other Financing Activity | -5,366 | 85,715 | 0 | 0 |
| Financing Cash Flow | $140,140 | $85,715 | $N/A | $N/A |
| Beginning Cash Position | 63,250 | 33,832 | N/A | N/A |
| End Cash Position | 168,198 | 63,250 | N/A | N/A |
| Net Cash Flow | $104,948 | $29,418 | $N/A | $N/A |
| Free Cash Flow | ||||
| Operating Cash Flow | -29,772 | -20,897 | N/A | N/A |
| Capital Expenditure | -10 | -20 | N/A | N/A |
| Free Cash Flow | -29,782 | -20,917 | 0 | 0 |